TabletsClinical Overview
Alfuzosin (10mg prolonged-release) and Dutasteride (0.5mg) Tablets is a fixed-dose combination combining a functionally uroselective alpha-1 blocker with a dual 5-alpha reductase inhibitor. Alfuzosin relaxes prostatic smooth muscle and decreases bladder outlet resistance without inhibiting alpha-1A subtype exclusively, preserving normal ejaculation in most men. Dutasteride halts DHT-mediated androgenic proliferation, reducing prostate volume. Indicated for symptomatic BPH with enlarged prostate gland.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily immediately after the same meal each day (preferably dinner) with a glass of water. Swallow whole; do not chew or crush prolonged-release matrix.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, headache, upper respiratory tract infection, fatigue, erectile dysfunction, reduced libido. Rare/Severe: Orthostatic hypotension, syncope, QT prolongation, priapism, and IFIS during eye surgery.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in moderate-to-severe hepatic impairment and co-administration with potent CYP3A4 inhibitors (ketoconazole, ritonavir). Alfuzosin may prolong QTc interval; caution in patients with underlying cardiac conduction disorders.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Tamsulosin Hydrochloride (Modified Release) 0.4mg + Dutasteride 0.5mg Tablets
Tamsulosin Hydrochloride (0.4mg modified-release) and Dutasteride (0.5mg) Tablets/Capsules is a synergistic dual-action therapy on the WHO Model List framework for symptomatic Benign Prostatic Hyperplasia (BPH). Tamsulosin is a uroselective alpha-1A/1D adrenergic receptor antagonist that relaxes smooth muscle in the prostate stroma, prostatic capsule, and bladder neck, rapidly improving urinary peak flow rates and relieving lower urinary tract symptoms (LUTS). Dutasteride is a potent dual type 1 and type 2 5-alpha reductase inhibitor (5-ARI) that suppresses dihydrotestosterone (DHT) synthesis by >90%, progressively shrinking enlarged prostate volume over 3-6 months. Indicated for moderate-to-severe BPH with enlarged prostate (volume >30cc) to reduce the risk of acute urinary retention (AUR) and the need for BPH-related surgery (TURP).
Alfuzosin Prolonged-release Tablets 10mg
Alfuzosin Prolonged-Release Tablets (10mg) is a quinazoline-derivative, functionally uroselective alpha-1 adrenergic antagonist on the WHO Model List framework. It distributes preferential clinical relaxant action to prostatic and trigonal smooth muscle, reducing bladder outlet obstruction without predominantly altering ejaculatory duct innervation, resulting in a very low incidence of retrograde ejaculation (<1-2%). Indicated for the treatment of moderate-to-severe symptoms of Benign Prostatic Hyperplasia (BPH) and as adjunctive therapy with catheterization for acute urinary retention related to BPH.
Dutasteride Capsule 0.5 mg
Dutasteride Capsules (0.5mg) is a synthetic 4-aza-steroid dual inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes on the WHO Model List of Essential Medicines. It blocks the enzymatic intracellular conversion of testosterone to 5-alpha-dihydrotestosterone (DHT) in the prostate, skin, and liver, suppressing circulating DHT levels by >90% and intraprostatic DHT by >94%. This induces apoptotic involution of prostatic epithelial cells, progressively reducing total prostate volume by ~25% and reducing risk of urinary retention and TURP surgery. Indicated for treatment of symptomatic BPH in men with enlarged prostate.
Silodosin 4mg + Dutasteride 0.5mg Capsules
Silodosin (4mg/8mg) and Dutasteride (0.5mg) Capsules is an advanced fixed-dose combination for Benign Prostatic Hyperplasia (BPH). Silodosin is an ultra-selective alpha-1A adrenergic receptor antagonist (>160-fold selectivity over alpha-1B receptors), providing targeted bladder neck and prostatic relaxation with minimal vascular hypotensive effects. Dutasteride blocks both 5-alpha reductase isoforms, permanently lowering circulating and intraprostatic DHT to shrink prostate gland tissue. Indicated for treatment of moderate-to-severe LUTS associated with prostatic enlargement.